Retraction notice to “Bullous pemphigoid: Associations and management guidelines: Facts and controversies” [Clin. Dermatol. 31(2013) 400-412](S0738081X13000084)(10.1016/j.clindermatol.2013.01.007);Bullous pemphigoid: Associations and management guidelines: Facts and controversies

Clinics in Dermatology

Volumn 31, Issue 4, 2013, Pages 400-412

  Ruocco, Eleonora ^a   Wolf, Ronni ^b   Caccavale, Stefano ^a   Brancaccio, Gabriella ^a   Ruocco, Vincenzo ^a   Lo Schiavo, Ada ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DAPSONE; DEFLAZACORT; DOXYCYCLINE; ERYTHROMYCIN; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMALIZUMAB; PREDNISONE; RITUXIMAB; TETRACYCLINE;

ALOPECIA; AMENORRHEA; ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHENIA; AUTOIMMUNE DISEASE; AZOOSPERMIA; BACKACHE; BONE MARROW SUPPRESSION; BRONCHOSPASM; BULLOUS PEMPHIGOID; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILL; COGNITIVE DEFECT; DERMATITIS; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DISEASE CONTROL; DIZZINESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; ERYTHEMA; ERYTHEMA MULTIFORME; FATIGUE; FLUSHING; GASTROINTESTINAL SYMPTOM; HAIR DISEASE; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HEMOLYSIS; HEMORRHAGIC CYSTITIS; HEPATITIS B; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOTENSION; IMMUNOPATHOLOGY; INFECTION; INFERTILITY; INFUSION RELATED REACTION; INTERSTITIAL PNEUMONIA; INTESTINE OBSTRUCTION; KIDNEY FAILURE; LEPROSY; LETHARGY; LEUKOPENIA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER TOXICITY; LOW DRUG DOSE; LUNG DISEASE; LYMPHOCYTOPENIA; LYMPHOMA; MALARIA; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; METHEMOGLOBINEMIA; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MYALGIA; MYOPATHY; NAIL DISEASE; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUTROPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; PAIN; PANCYTOPENIA; PARANEOPLASTIC SYNDROME; PATHOGENESIS; PEMPHIGUS VULGARIS; PERIPHERAL NEUROPATHY; PHLEBITIS; PHOTOSENSITIVITY; PIGMENT DISORDER; PLASMAPHERESIS; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; QUALITY OF LIFE; RADIATION INJURY; RECOMMENDED DRUG DOSE; REPRODUCTIVE TOXICITY; RHINITIS; RIGOR; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; SKIN DISEASE; SKIN LUPUS ERYTHEMATOSUS; STOMACH PAIN; STOMACH ULCER; SURVIVAL RATE; THROAT IRRITATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URTICARIA; VASCULITIS; VIRUS INFECTION; VOMITING;

EID: 84879584628     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2017.11.001     Document Type: Erratum

References (43)

1. Ljubojevic S., Lipozenčić J. Autoimmune bullous diseases associations. Clin Dermatol 2012, 30:17-33.
2. Cordel N., Chosidow O., Hellot M.F., et al. Neurological disorders in patients with bullous pemphigoid. Dermatology 2007, 215:187-191.
3. Chen Y.J., Wu C.Y., Lin M.W., et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol 2011, 165:593-599.
4. Stinco G., Codutti R., Scarbolo M., Valent F., Patrone P. A retrospective epidemiological study on the association of bullous pemphigoid and neurological diseases. Acta Derm Venereol 2005, 85:136-139.
5. Langan S.M., Groves R.W., West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol 2011, 131:631-636.
6. Taghipour K., Chi C.C., Vincent A., Groves R., Venning V., Wojnarowska F. The association of bullous pemphigoid with cerebrovascular disease and dementia. Arch Dermatol 2010, 146:1251-1254.
7. Bastuji-Garin S., Joly P., Lemordant P., et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol 2011, 131:637-643.
8. Korman N.J., Stanley J.R., Woodley D.T. Coexistence of pemphigus foliaceus and bullous pemphigoid. Arch Dermatol 1991, 127:387-390.
9. Leibovici V., Ron N., Goldenhersh M., Holubar K. Coexistence of pemphigus and bullous pemphigoid. Int J Dermatol 1989, 28:259-260.
10. Marzano A.V., Tedeschi A., Fanoni D., et al. Activation of blood coagulation in bullous pemphigoid: role of eosinophils, and local and systemic implications. Br J Dermatol 2009, 160:266-272.
11. Jedlickova H., Hlubinka M., Pavlik T., Semradova V., Budinska E., Vlasin Z. Bullous pemphigoid and internal diseases-a case-control study. Eur J Dermatol 2010, 20:96-101.
12. Langan S.M., Hubbard R., Fleming K., West J. A population-based study of acute medical conditions associated with bullous pemphigoid. Br J Dermatol 2009, 161:1149-1152.
13. Savin J.A. The events leading to the death of patients with pemphigus and pemphigoid. Br J Dermatol 1979, 101:521-534.
14. Chorzelski T.P., Jablonska S., Maciejowska E., Beutner E.H., Wronkowski L. Coexistence of malignancies with bullous pemphigoid. Arch Dermatol 1978, 114:964.
15. Cozzani E., Parodi A., Rebora A., et al. Bullous pemphigoid in Liguria: a 2-year survey. J Eur Acad Dermatol Venereol 2001, 15:317-319.
16. Marazza G., Pham H.C., Schärer L., et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 2009, 161:861-868.
17. Lindelöf B., Islam N., Eklund G., Arfors L. Pemphigoid and cancer. Arch Dermatol 1990, 126:66-68.
18. Ahmed A.R., Maize J.C., Provost T.T. Bullous pemphigoid: clinical and immunologic follow-up after successful therapy. Arch Dermatol 1977, 113:1043-1046.
19. Stone S.P., Schroeter A.L. Bullous pemphigoid and associated malignant neoplasms. Arch Dermatol 1975, 111:991-994.
20. Chang Y.T., Liu H.N., Wong C.K. Bullous pemphigoid-a report of 86 cases from Taiwan. Clin Exp Dermatol 1996, 21:20-22.
21. Lim C.C., MacDonald R.H., Rook A.J. Pemphigoid eruptions in the elderly. Trans St Johns Hosp Dermatol Soc 1968, 54:148-151.
22. Parsons R.L., Savin J.A. Pemphigoid and malignancy. Br J Cancer 1968, 22:669-672.
23. Paslin D.A. Bullous pemphigoid and hypernephroma: a critical review of bullous pemphigoid and malignancy. Cutis 1973, 12:554-555.
24. Ebner H., Spängler E. An investigation of the association between bullous pemphigoid and malignant disease. Wien Klin Wochenschr 1974, 86:449-452.
25. Moss A.A., Hanelin L.G. Occult malignant tumors in dermatologic disease. The futility of radiological search. Radiology 1977, 123:69-71.
26. Person J.R., Rogers R.S. Bullous and cicatricial pemphigoid. Clinical, histopathologic, and immunopathologic correlations. Mayo Clin Proc 1977, 52:54-66.
27. Hodge L., Marsden R., Black M.M., Bhogal B., Corbett M.F. Bullous pemphigoid: the frequency of mucosal involvment and concurrent malignancy related to indirect immunofluorescence findings. Br J Dermatol 1981, 105:65-69.
28. Venencie P.Y., Rogers R.S., Schroeter A.L. Bullous pemphigoid and malignancy: relationship to indirect immunofluorescent findings. Acta Derm Venereol 1984, 64:316-319.
29. Venning V.A., Wojnarowska F. The association of bullous pemphigoid and malignant disease: a case control study. Br J Dermatol 1990, 123:439-445.
30. Ogawa H., Sakuma M., Morioka S., et al. The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan. J Dermatol Sci 1995, 9:136-141.
31. Ruocco V., Brunetti G., Puca R.V., Ruocco E. The immunocompromised district: a unifying concept for lymphoedematous, herpes-infected and otherwise damaged sites. J Eur Acad Dermatol Venereol 2009, 23:1364-1373.
32. Lo Schiavo A., Ruocco E., Brancaccio G., Caccavale S., Ruocco V., Wolf R. Bullous pemphigoid: etiology, pathogenesis, and inducing factors. Facts and controversies. Clin Dermatol 2013, 31:391-399.
33. Culton D.A., Diaz L.A. Treatment of subepidermal immunobullous diseases. Clin Dermatol 2012, 30:95-102.
34. Meurer M. Immunosuppressive therapy for autoimmune bullous diseases. Clin Dermatol 2012, 30:78-83.
35. Joly P., Roujeau J.C., Benichou J., et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002, 346:321-327.
36. Lo Schiavo A., Puca R.V., Ruocco V., Ruocco E. Adjuvant drugs in autoimmune bullous diseases, efficacy versus safety: Facts and controversies. Clin Dermatol 2010, 28:337-343.
37. Sehgal VN, Verma P. Leflunomide: dermatologic perspective. J. Dematolog Treat 2011. Posted online on July 31, 2011. http://dx.doi.org/10.3109/09546634.2011.595383.
38. Lo Schiavo A., Muto L., Ruocco E. Terapie alternative delle malattie bollose autoimmuni. G Ital Dermatol Venereol 2002, 137:105-115.
39. Gürcan H.M., Ahmed A.R. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol 2009, 16:723-731.
40. Tirado-Sánchez A., Díaz-Molina V., Ponce-Olivera R.M. Efficacy and safety of azathioprine and dapsone as an adjuvant in the treatment of bullous pemphigoid. Allergol Immunopathol 2012, 40:152-155.
41. Monk E., Shalita A., Siegel D.M. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharmacol Res 2011, 63:130-145.
42. Kasperkiewicz M., Shimanovich I., Ludwig R.J., Rose C., Zillikens D., Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 2011, 65:552-558.
43. Fairley J.A., Baum C.L., Brandt D.S., Messingham K.A. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol 2009, 123:704-705.